TOKYO, Mar 25 (Pulse News Wire) – Nxera Pharma CO.,LTD. (4565.T) announced significant updates to its leadership structure following the March 25 extraordinary shareholders' meeting and subsequent board meeting.
Christopher Kargil, CEO and President, stated, “We are delighted to welcome Mr. Masao Shozoka as a new director, leveraging his extensive experience in corporate management, technology research and development, strategic planning, and marketing.” Key appointments effective March 25 include: Directors: - Reappointed: Christopher Kargil (Representative Director) - Reappointed: David Roblin (Outside Director) - Reappointed: Rolf Sodastrom (Outside Director) - Reappointed: Hideo Tomita (Outside Director) - Reappointed: Naoko Shimura (Outside Director) - Reappointed: Nicola Labson (Outside Director) - Newly appointed: Masao Shozoka (Outside Director) Executive Team: - CEO and Representative Director: Christopher Kargil - Chief Financial Officer: Hirofumi Nomura - Chief Operating Officer and NPJ President: Toshihiro Maeda - Chief Scientific Officer and NPUK President: Patrick Forsch - Chief Accounting Officer: Keiran Johnson - Chief of Staff: Candace Chong - General Counsel: Manako Nakatomo Nxera Pharma focuses on delivering innovative specialty medicines addressing unmet needs globally through advanced drug discovery platforms and partnerships with major pharmaceutical companies.
With headquarters in Tokyo, Osaka, London, Cambridge, Basel, and Seoul, the company continues to expand its pipeline of promising therapeutic candidates across various disease areas.
🟢 Confidence: High AI-translated content.